| Name | Title | Contact Details |
|---|
Medico Mart Inc is a Waukesha, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Blue Shield of California, we`re focused on fundamentally improving the ways in which members can access care and use their coverage. We`re investing in talented employees and new technologies to create an unrivaled member experience that elevates expectations and achieves our mission of making health care more accessible and affordable than ever. Today we are the third-largest health plan in the state and we`re dedicated to transforming the healthcare industry. Headquartered in San Francisco, with 18 additional offices across California, we`re proud to service over 4 million members and employ more than 6,000 people. We are an independent member of the Blue Shield Association. Blue Shield of California complies with applicable state laws and federal civil rights laws, and does not discriminate on the basis of race, color, national origin, ancestry, religion, sex, marital status, gender, gender identity, sexual orientation, age, or disability. Blue Shield of California cumple con las leyes estatales y las leyes federales de derechos civiles vigentes, y no discrimina por motivos de raza, color, país de origen, ascendencia, religión, sexo, estado civil, género, identidad de género, orientación sexual, edad ni discapacidad.
ATS Health Services is a Jacksonville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vibrant Health is a company that sells health and wellness products online, including supplements, superfoods, and more.
Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates. These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending. Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™. The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee. Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema. Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.